Browsing Radiotherapy and Imaging by author "Eeles, Rosalind"
Now showing items 81-100 of 148
-
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Silvestri, V; Barrowdale, D; Mulligan, AM; Neuhausen, SL; Fox, S; et al. (BMC, 2016-02-09)BACKGROUND: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 ... -
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; et al. (ELSEVIER, 2020-04-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ... -
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; et al. (ELSEVIER SCIENCE BV, 2018-02-01)BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of ... -
Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium.
Salmon, C; Song, L; Muir, K; UKGPCS Collaborators,; Pashayan, N; et al. (SPRINGER, 2021-07-18)While being in a committed relationship is associated with a better prostate cancer prognosis, little is known about how marital status relates to its incidence. Social support provided by marriage/relationship could promote ... -
Men with a susceptibility to prostate cancer and the role of genetic based screening.
Eeles, R; Ni Raghallaigh, H (AME PUBL CO, 2018-02-01)Prostate cancer is the second most common malignancy affecting men worldwide, and the commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been made in the past decade. Improvements ... -
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
Qian, F; Rookus, MA; Leslie, G; Risch, HA; Greene, MH; et al. (SPRINGERNATURE, 2019-07-16)BACKGROUND: Height and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown. METHODS: We applied a ... -
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
Tubio, JMC; Li, Y; Ju, YS; Martincorena, I; Cooke, SL; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2014-08-01)Long interspersed nuclear element-1 (L1) retrotransposons are mobile repetitive elements that are abundant in the human genome. L1 elements propagate through RNA intermediates. In the germ line, neighboring, nonrepetitive ... -
Mutational signatures of ionizing radiation in second malignancies.
Behjati, S; Gundem, G; Wedge, DC; Roberts, ND; Tarpey, PS; et al. (NATURE PUBLISHING GROUP, 2016-09-12)Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched ... -
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Rebbeck, TR; Friebel, TM; Friedman, E; Hamann, U; Huo, D; et al. (WILEY-HINDAWI, 2018-05-01)The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of ... -
Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening.
Petralia, G; Koh, D-M; Attariwala, R; Busch, JJ; Eeles, R; et al. (RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2021-06-01)Acknowledging the increasing number of studies describing the use of whole-body MRI for cancer screening, and the increasing number of examinations being performed in patients with known cancers, an international ... -
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study.
Schrijver, LH; Olsson, H; Phillips, K-A; Terry, MB; Goldgar, DE; et al. (OXFORD UNIV PRESS, 2018-04-01)BACKGROUND: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear. METHODS: Breast camcer risk associations were estimated from ... -
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Southey, MC; Goldgar, DE; Winqvist, R; Pylkäs, K; Couch, F; et al. (BMJ PUBLISHING GROUP, 2016-12-01)BACKGROUND: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are ... -
Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, (NATURE PORTFOLIO, 2020-02-06)Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of ... -
Patterns of recurrence after prostate bed radiotherapy.
Brand, DH; Parker, JI; Dearnaley, DP; Eeles, R; Huddart, R; et al. (ELSEVIER IRELAND LTD, 2019-12-01)BACKGROUND AND PURPOSE: Prostate bed radiotherapy is a standard treatment after radical prostatectomy. Recent evidence suggests that, for patients with a PSA > 0.34 ng/ml, the radiotherapy treatment volume should include ... -
Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.
Karunamuni, RA; Huynh-Le, M-P; Fan, CC; Thompson, W; Lui, A; et al. (SPRINGERNATURE, 2021-06-14)BACKGROUND: We previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of ... -
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira, M; Khan, A; Thomas, K; Truelove, L; McNair, H; et al. (ELSEVIER SCIENCE INC, 2017-12-01)PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, ... -
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.
Huynh-Le, M-P; Fan, CC; Karunamuni, R; Thompson, WK; Martinez, ME; et al. (NATURE PORTFOLIO, 2021-02-23)Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and ... -
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
Seibert, TM; Fan, CC; Wang, Y; Zuber, V; Karunamuni, R; et al. (BMJ PUBLISHING GROUP, 2018-01-10)OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to ... -
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
Barnes, DR; Rookus, MA; McGuffog, L; Leslie, G; Mooij, TM; et al. (ELSEVIER SCIENCE INC, 2020-10-01)PURPOSE: We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. METHODS: ... -
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender, T; Emberton, M; Morris, S; Eeles, R; Kote-Jarai, Z; et al. (PUBLIC LIBRARY SCIENCE, 2019-12-01)BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of ...